marked.bio

Company

3H (Suzhou) Pharmaceuticals

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 2 trials shown

  1. A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

    Recruiting Phase 1/2 3H (Suzhou) Pharmaceuticals Started 2024Primary completion 2028-06 NCT06378593

    3HP-2827

    A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

    FGFR2 fusion or rearrangementSolid Tumors With FGFR2 Alterations, Adult

  2. A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

    Not yet recruiting Phase 1 3H (Suzhou) Pharmaceuticals Started 2026Primary completion 2028-03 NCT06287918

    3HP-2827

    …-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

    FGFR2 fusion or rearrangementSolid Tumors With FGFR2 Alterations, Adult